Myovant Sciences Ltd
 | |
| | |
| Myovant Sciences Ltd | |
|---|---|
| Type | Public |
| Industry | Biopharmaceutical |
| Founded | 2016 |
| Headquarters | Hamilton, Bermuda. |
| Key people | Lynn Seely M.D. (CEO, President and Executive Director), Frank L. Karbe (Principal Financial and Accounting Officer), Marianne L. Romeo [1] |
| Number of employees | 9 |
Myovant Sciences is focused on innovative treatments for women's health conditions and prostate cancer. The company's lead program is relugolix, a phase 3 drug candidate for multiple indications, including uterine fibroids, endometriosis and prostate cancer. Myovant was formed through a strategic partnership between Roivant Sciences and Takeda.[2] [3]
Osaka, Japan-based Takeda Pharmaceutical Company (TKPYY) and Hamilton, Bermuda-based Roivant Sciences came together and launched Myovant Sciences.Roivant Sciences spun out of Axovant Sciences (AXON) in May 2014. [4]
The company recently filed for an IPO of up to $172.5 million; applied to list common shares on NYSE under symbol "MYOV".
Contents
Products
Its lead product candidate is Relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The company also intends to develop RVT-602, an oligopeptide kisspeptin analog, for the treatment of female infertility as part of assisted reproduction.
Controversies
None Reported
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| April 18, 2023 | fundamentalsbot | Myovant Sciences Ltd's quarterly revenue growth rate YoY of 84.10% ranked 487 out of 5747 companies in our database… https://t.co/EIT9Eq8j7f |
| April 15, 2023 | stockresearchhq | Myovant Sciences Ltd $MYOV quarterly revenue growth rate YoY of 84.10% ranked
⭐⭐⭐⭐⭐ in our db. Impressive! https://t.co/1wyS5rsKay |
| April 15, 2023 | fundamentalsbot | Myovant Sciences Ltd's quarterly revenue growth rate YoY of 84.10% ranked 490 out of 5747 companies in our database… https://t.co/YuWcxxrefj |
Top 5 Recent News Headlines
- Myovant Sciences Ltd. Announces Board Appointments - Myovant Sciences Ltd. has announced additions to its Board of Directors. The Board of Directors Comprised of Biopharmaceutical and Healthcare Industry Veterans. [5]
- Myovant Sciences files for IPO - Files for IPO of up to $172.5 million; applied to list common shares on NYSE under symbol "MYOV" [6]
- Former Medivation (MDVN) CMO Takes Helm at Roivant Sciences-Takeda (TKPYY)'s Newly Launched Company Myovant Sciences - Osaka, Japan-based Takeda Pharmaceutical Company (TKPYY) and Hamilton, Bermuda-based Roivant Sciences, announced that they had together launched Myovant Sciences. [7]
- Roivant Sciences and Takeda Launch Myovant Sciences to Develop Innovative Therapeutics for Women's Health and Prostate Cancer - - Myovant to conduct global phase 3 programs of relugolix, a potential best-in-class GnRH antagonist for the treatment of uterine fibroids, endometriosis and prostate cancer. [8]
- Myovant Sciences Ltd. Auditor Raises 'Going Concern' Doubt - In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. [9]
References
- ↑ http://myovant.com/management
- ↑ http://www.forbes.com/sites/nathanvardi/2016/07/13/billionaire-andreas-halvorsens-hedge-fund-backs-private-biotech-roivant-sciences/#2f3e6a166443
- ↑ http://www.prnewswire.com/news-releases/roivant-sciences-and-takeda-launch-myovant-sciences-to-develop-innovative-therapeutics-for-womens-health-and-prostate-cancer-300279891.html
- ↑ http://www.biospace.com/News/former-medivation-cmo-takes-helm-at-roivant/422106
- ↑ http://www.bloomberg.com/Research/stocks/private/snapshot.asp?privcapId=403430039
- ↑ http://www.reuters.com/article/idUSFWN1C60QX
- ↑ http://www.biospace.com/News/former-medivation-cmo-takes-helm-at-roivant/422106
- ↑ http://www.prnewswire.com/news-releases/roivant-sciences-and-takeda-launch-myovant-sciences-to-develop-innovative-therapeutics-for-womens-health-and-prostate-cancer-300279891.html
- ↑ http://www.bloomberg.com/Research/stocks/private/snapshot.asp?privcapId=403430039
Top Authors
Verification history
3,002 days ago- View all verifications
